K. Khunti

First name
Last name
Conrad, N., Misra, S., . Y. Verbakel, J., Verbeke, G., Molenberghs, G., Taylor, P. N., et al. (2023). Incidence, prevalence, and co-occurrence of autoimmune disorders over time and by age, sex, and socioeconomic status: a population-based cohort study of 22 million individuals in the UK. Lancet. http://doi.org/10.1016/s0140-6736(23)00457-9
Ling, S., Zaccardi, F., Issa, E., Davies, M. J., Khunti, K., & Brown, K. (2023). Inequalities in cancer mortality trends in people with type 2 diabetes: 20 year population-based study in England. Diabetologia. http://doi.org/10.1007/s00125-022-05854-8
Meffen, A., Sayers, R. D., Gillies, C. L., Khunti, K., & Gray, L. J. (2022). Are major lower extremity amputations well recorded in primary care electronic health records?: Insights from primary care electronic health records in England. Prim Health Care Res Dev, 23, e77. http://doi.org/10.1017/s1463423622000718
Mizani, M. A., Dashtban, A., Pasea, L., Lai, A. G., Thygesen, J., Tomlinson, C., et al. (2022). Using national electronic health records for pandemic preparedness: validation of a parsimonious model for predicting excess deaths among those with COVID-19-a data-driven retrospective cohort study. J R Soc Med, 1410768221131897. http://doi.org/10.1177/01410768221131897
Karsanji, U., Evans, R. A., Quint, J. K., Khunti, K., Lawson, C. A., Petherick, E., et al. (2022). Mortality associated with metabolic syndrome in people with COPD managed in primary care. Erj Open Res, 8. http://doi.org/10.1183/23120541.00211-2022
Bidulka, P., Mathur, R., Lugo-Palacios, D. G., O'Neill, S., Basu, A., Silverwood, R. J., et al. (2022). Ethnic and socioeconomic disparities in initiation of second-line antidiabetic treatment in people with type 2 diabetes in England: a cross-sectional study. Diabetes Obes Metab. http://doi.org/10.1111/dom.14874
Idris, I., Zhang, R., Mamza, J. B., Ford, M., Morris, T., Banerjee, A., & Khunti, K. (2021). Lower risk of hospitalization for heart failure, kidney disease and death with sodium-glucose co-transporter-2 inhibitors compared with dipeptidyl peptidase-4 inhibitors in type 2 diabetes regardless of prior cardiovascular or kidney disease. Diabetes Obes Metab, 23, 2207-2214. http://doi.org/10.1111/dom.14437
Wilkinson, T. J., Miksza, J., Zaccardi, F., Lawson, C., Nixon, A. C., Young, H. M. L., et al. (2022). Associations between frailty trajectories and cardiovascular, renal, and mortality outcomes in chronic kidney disease. J Cachexia Sarcopenia Muscle. http://doi.org/10.1002/jcsm.13047
Idris, I., Zhang, R., Mamza, J. B., Ford, M., Morris, T., Banerjee, A., & Khunti, K. (2022). Significant reduction in chronic kidney disease progression with sodium-glucose cotransporter-2 inhibitors compared to dipeptidyl peptidase-4 inhibitors in adults with type 2 diabetes in a UK clinical setting. Diabetes Obes Metab. http://doi.org/10.1111/dom.14799
Dashtban, A., Mizani, M. A., Denaxas, S., Nitsch, D., Quint, J., Corbett, R., et al. (2022). A retrospective cohort study measured predicting and validating the impact of the COVID-19 pandemic in individuals with chronic kidney disease. Kidney Int. http://doi.org/10.1016/j.kint.2022.05.015